Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

Virtual Education Program - COLT Meeting 2014 (Session 4)

-- Virtual Education Program: 2015 Edition 

 

Presentations from a CML Opinion Leader Meeting

We are pleased to make available a new series of presentations from the COLT Meeting 2014, an annual CML Opinion Leader Training that took place in Adelaide (Australia). Modules currently featured include; high risk CML, optimizing therapy, front line therapy in CML chronic phase and new developments in CML - all presented by leaders in the field. 

David RossAgnes YONG w labcoat1

Dr David Ross            Dr Agnes Yong

 

Session 4: New developments in CML

  • Is CML a curable disease? 
    (Dr David Ross)
  • Transplant and immunotherapy in CML
    (Dr Agnes Yong)

 

VEP Modern Diagnostics: Biomarkers

Deborah White                                                                

 

 

 

Biomarkers and response monitoring beyond PCR?
Deborah White - SAHMRI, University of Adelaide

  • Predictive biomarkers
  • Cytokines, growth factors and chemokines: TGF and IL6
  • KIR2DS1 genotype and inferior cytogenetic response: SPIRIT1
  • CIP2A and response
  • Imatinib drug levels and compliance
     

Virtual Education Program - COLT Meeting 2014 (Session 3)

 

                    

 

Collage COLT Session3

     A/Prof. Branford       Prof. Hughes

                

 

 

 

Session 3: High risk CML

  • Mechanisms of resistance to TKI therapy 
    (A/Prof. Susan Branford)
  • When frontline TKI therapy fails
    (Prof. Timothy Hughes)

 

VEP Modern Diagnostics: Molecular Monitoring in CML

 

 We are very grateful for the support of Brandcast media to produce this web stream
VEP Müller

 

 

  

         

 

 

Molecular monitoring in CML - getting to a safe place
Martin C. Müller, Institute for Hematology and Oncology (IHO) and Medical Faculty Mannheim, University of Heidelberg, Germany 

  • What do we consider safe?
  • Cytogenetic and molecular monitoring: European LeukemiaNet recommendations
  • Molecular monitoring every 3 months - enough for all patients?
  • Achieving deep remissions
  • Definitions of molecular response
  • Compliance check
  • Conclusions

Virtual Education Program - COLT Meeting 2014 (Session 2)

 

Jorge Cortes 2013                     Prof. Jorge Cortes                             

 

 

    Session 2: Optimizing Therapy in CML

  • Evolution of frontline therapy in CML
  • Treatment outcomes for different time periods
  • Factors predicting optimal response
  • Treatment choices in CML including 2nd/3rd generation of TKI's
  • Risks and outcomes after treatment discontinuation 

Virtual Education Program - COLT Meeting 2014 (Session 1)

 

Collage COLT module 2         Prof. Melo             Prof. Hughes     A/Prof. Branford

                     

Session 1: Front line Therapy of CML-CP

  • Addressing key biological questions in CML 
    (Prof. Junia Melo)
  • Risk profiles, molecular targets, pharmacokinetics 
    (Prof. Timothy Hughes)
  • The importance of deep molecular response in CML patients 
    (A/Prof. Susan Branford)